<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="371849">
  <stage>Registered</stage>
  <submitdate>5/12/2016</submitdate>
  <approvaldate>8/12/2016</approvaldate>
  <actrnumber>ACTRN12616001687482</actrnumber>
  <trial_identification>
    <studytitle>Restoring the function of brain networks in Obsessive-Compulsive Disorders using non-invasive brain stimulation </studytitle>
    <scientifictitle>Effects of transcranial magnetic stimulation on brain network dynamics and symptoms of Obsessive-Compulsive Disorder</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Obsessive Compulsive Disorder</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Anxiety</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Other mental health disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Participants will complete an initial neurocognitive assessment and a baseline imaging session. Participants will then be pseudo-randomly assigned to either the 'active' Transcranial Magnetic Stimulation (TMS) group or the placebo TMS group. Following the scan, participants will begin a 4-week protocol of repetitive TMS. TMS will be administered by trained personnel. Participants in the active TMS condition will undergo a 600-pulses theta burst stimulation to the prefrontal cortex.This procedure will involve the participant coming to the QIMR Berghofer Medical Research Institute five days per week (Mon-Fri) for a ~45min TMS session. After the 4-week TMS regime, participants will undergo a second imaging session, immediately followed by a final clinical assessment. Six months after completion of the intervention, participants will participate in a follow-up cognitive assessment.</interventions>
    <comparator>Placebo stimulation will be administered with a specific coil that is made by the same manufacturer. This coil mimics the noise and effects of the real TMS but does not affect the neural activity of the targeted area. 

Participant coming to the QIMR Berghofer Medical Research Institute five days per
week (Mon-Fri) for a 30-45min TMS session. </comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Devices</interventioncode>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Changes in functional brain connectivity between the striatum and the TMS cortical target assessed using magnetic resonance imaging. The baseline and post-intervention imaging sessions will be used. </outcome>
      <timepoint>Baseline and 4 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Changes in Y-BOCS score after the TMS intervention. The Y-BOCS is a 10-item scale administered as a semi structured interview. The scale assesses the severity of obsessions and compulsions. The Y-BOCS is the standard test to evaluate OCD. </outcome>
      <timepoint>Baseline, 4 weeks and 6 months. (The cognitive assessment will take place pre and post TMS intervention, as well as 6 months after the intervention.)</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Changes in structural brain connectivity between the striatum and the TMS cortical target assessed using magnetic resonance imaging. The baseline and post-intervention imaging sessions will be used. </outcome>
      <timepoint>Baseline and 4 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>* Belief domains of the Obsessive Beliefs Questionnaire-44 (OBQ-44)

</outcome>
      <timepoint>Baseline, week 4 and 6 months.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>*The ObsessiveCompulsive Inventory, short version (OCI-R)</outcome>
      <timepoint>Baseline, week 4 and 6 months.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>*Montgomery Asberg Depression Scale (MADS)</outcome>
      <timepoint>Baseline, week 4 and 6 months.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>*Hamilton Anxiety Rating Scale (HAM_A)</outcome>
      <timepoint>Baseline, week 4 and 6 months.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>*Hospital Anxiety and Depression Scale (HADS)</outcome>
      <timepoint>Baseline, week 4 and 6 months.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>*Weischler Intelligence Scale (WAS-II)</outcome>
      <timepoint>Baseline, week 4 and 6 months.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>To be eligible for participation in the study, male and female participants must meet
all the following criteria:
1. Diagnosis of primary Obsessive-compulsive disorder (OCD) according to
the DSM-V criteria.
2. Yale and Brown Obsessive Compulsive scale (Y-BOCS) score between
17and 31 (i.e., moderate to severe symptomatology).
3. Duration of OCD greater than 1 year.
4. Stable Selective Serotonin Reuptake Inhibitors (SSRI) treatment for at
least 1 month.
5. Age: 18-50
6. Participants must be available to come to QIMRB daily (Mon-Fri) for 4
weeks. The TMS stimulation will take approximatively 30-45 minutes.
7. Participants must be able to provide informed consent</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>50</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Potential participants will be ineligible for recruitment if they:
*have had a change to pharmaceutical treatment in the past month.
*are pregnant or trying to fall pregnant?
*ever attempted suicide?
*ever been diagnosed with a psychotic disorder?
*ever experienced a manic episode?
*ever experienced a seizure?
*has a neurological disorder?
*ever experienced a traumatic head injury?
*ever been diagnosed with a substance abuse disorder?
*suffers from claustrophobia?
*has any contraindications to MRI and TMS</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>15/12/2016</anticipatedstartdate>
    <actualstartdate>21/04/2017</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>50</samplesize>
    <actualsamplesize />
    <currentsamplesize>3</currentsamplesize>
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other Collaborative groups</primarysponsortype>
    <primarysponsorname>QIMR Berghofer Medical Research Institute</primarysponsorname>
    <primarysponsoraddress>300 Herston Rd, Herston QLD 4006</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health &amp; Medical Research Council (NHMRC)</fundingname>
      <fundingaddress>GPO Box 1421 Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Obsessive-compulsive disorder (OCD) is a severe mental illness that can
dramatically reduce quality of life. Despite use of best practise clinical management,
many patients continue to experience symptoms and associated disability. Recent
neuroimaging studies have shown that OCD is characterised by significant, yet
specific, changes in the activity of macroscopic brain networks comprising of frontal
and subcortical brain regions. Parallel to these developments, non-invasive brain
stimulation techniques such as transcranial magnetic stimulation (TMS) have
emerged as viable tools to modulate the activity of brain networks in both healthy and
pathological populations. TMS has an established clinical role in the treatment of
major depressive disorder. This project aims to assess the possible use of local TMS
to selectively restore altered brain network activity and improve symptoms in people
with OCD. To achieve this goal outpatient with OCD will be asked to undertake
functional magnetic resonance imaging (fMRI) before and after a TMS intervention. If
successful, the proposed project will represent the first demonstration that TMS can
be used to selectively restore the altered function of widespread neural networks and
improve symptoms in people diagnosed with OCD. Such an outcome will be
instrumental to motivate larger clinical trials to test the efficiency of TMS as a
treatment, or complementary treatment, for OCD.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>QIMR Berghofer Human Research Ethics Committee</ethicname>
      <ethicaddress>300 Herston Rd, Herston QLD 4006</ethicaddress>
      <ethicapprovaldate>8/12/2016</ethicapprovaldate>
      <hrec>P2253</hrec>
      <ethicsubmitdate>29/11/2016</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Brisbane &amp; Womenâ€™s Hospital Human Research Ethics Committee</ethicname>
      <ethicaddress>HREC Office, Level 7, Block 7 RBWH
RGO Office, Level 4, UQCCR, RBWH
Butterfield Street, Herston Qld 402</ethicaddress>
      <ethicapprovaldate>23/11/2016</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>19/05/2016</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Luca Cocchi</name>
      <address>QIMR Berghofer Medical Institute
Bancroft Building, Level 12, 300 Herston Road
Brisbane QLD 4006</address>
      <phone>+617 3845 3008</phone>
      <fax />
      <email>luca.cocchi@qimrberghofer.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Luca Cocchi</name>
      <address>QIMR Berghofer Medical Institute
Bancroft Building, Level 12, 300 Herston Road
Brisbane QLD 4006</address>
      <phone>+61738453008</phone>
      <fax />
      <email>luca.cocchi@qimrberghofer.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Luca</name>
      <address>QIMR Berghofer Medical Institute
Bancroft Building, Level 12, 300 Herston Road
Brisbane QLD 4006</address>
      <phone>+61738453008</phone>
      <fax />
      <email>luca.cocchi@qimrberghofer.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Sashika Naidoo</name>
      <address>QIMR Berghofer Medical Research Institute
300 Herston Rd
Herston Qld 4006</address>
      <phone>+61 7 3362 0433</phone>
      <fax />
      <email>Sashika.Naidoo@qimrberghofer.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>